Sign In
Buy NURO
$4.58
+0 (+0%)
At Close: Jul 30, 2025
Addition of Quell® Platform Broadens electroCore's Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets Addition of Quell® Platform Broadens electroCore's B
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NeuroMetrix,
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURO
12:52pm, Wednesday, 18'th Dec 2024
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Secur
NURO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NeuroMetrix, Inc. Is Fair to Shareholders
08:04pm, Tuesday, 17'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NeuroMetrix, Inc. (NASDAQ: NURO) to electroCore, Inc. is fair to NeuroMetrix shareholders
NeuroMetrix to be Acquired by electroCore
04:05pm, Tuesday, 17'th Dec 2024
WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby ele
The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector
NeuroMetrix Q3 Loss Narrows Y/Y, Quell Sales Drives Growth
02:40pm, Wednesday, 06'th Nov 2024
Despite a 51% revenue dip, NURO narrowed losses in Q3 2024 by reducing operating expenses by 25%, offsetting the challenging revenue environment.
NeuroMetrix Reiterates its Review of Strategic Alternatives
02:47pm, Tuesday, 13'th Aug 2024
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives.
NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript
12:33am, Saturday, 10'th Aug 2024
NeuroMetrix, Inc. (NASDAQ:NURO ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - Founde
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call
02:03pm, Wednesday, 31'st Jul 2024
WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of
Head-To-Head Analysis: NeuroMetrix (NASDAQ:NURO) & Sharps Technology (NASDAQ:STSS)
01:36am, Monday, 20'th May 2024
NeuroMetrix (NASDAQ:NURO – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast t
NeuroMetrix Reports Q1 2024 Business Highlights
04:00pm, Wednesday, 15'th May 2024
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
08:00am, Friday, 19'th Apr 2024
Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enh
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
09:00am, Thursday, 14'th Mar 2024
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck al
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
09:00am, Wednesday, 13'th Mar 2024
NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.
